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ISSNObjectives: Many paediatric antiretroviral therapy (ART) programmes in Southern
Africa rely on CD4þ to monitor ART. We assessed the benefit of replacing CD4þ by
viral load monitoring.
Design: A mathematical modelling study.
Methods: A simulation model of HIV progression over 5 years in children on ART,
parameterized by data from seven South African cohorts. We simulated treatment
programmes with 6-monthly CD4þ or 6- or 12-monthly viral load monitoring. We
compared mortality, second-line ART use, immunological failure and time spent on
failing ART. In further analyses, we varied the rate of virological failure, and assumed
that the rate is higher with CD4þ than with viral load monitoring.
Results: About 7% of children were predicted to die within 5 years, independent of the
monitoring strategy. Compared with CD4þmonitoring, 12-monthly viral load monitor-
ing reduced the 5-year risk of immunological failure from 1.6 to 1.0% and the mean
time spent on failing ART from 6.6 to 3.6 months; 1% of children with CD4þ compared
with 12% with viral load monitoring switched to second-line ART. Differences became
larger when assuming higher rates of virological failure. When assuming higher
virological failure rates with CD4þ than with viral load monitoring, up to 4.2% of
children with CD4þ compared with 1.5% with viral load monitoring experienced
immunological failure; the mean time spent on failing ARTwas 27.3 months with CD4þ
monitoring and 6.0 months with viral load monitoring.
Conclusion: Viral load monitoring did not affect 5-year mortality, but reduced time on
failing ART, improved immunological response and increased switching to second-line
ART.  2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28:2451–2460Keywords: antiretroviral therapy, children, mathematical model, sub-Saharan
Africa, viral load monitoringippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
and Preventive Medicine, University of Bern, Bern, Switzerland, bRahima Moosa Hospital, University of the
hannesburg, cSchool of Public Health & Family Medicine, University of Cape Town, dKhayelitsha ART
cins Sans Frontie`res, eRed Cross Children’s Hospital, University of Cape Town, Cape Town, fTygerberg
l, University of Stellenbosch, Stellenbosch, gWits Reproductive Health & HIV Institute, Faculty of Health
ty of Witwatersrand, Johannesburg, hMcCord Hospital, Durban, and iDesmond Tutu HIV Centre, University of
Town, South Africa.
o Luisa Salazar-Vizcaya, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11,
rland.
8 67; e-mail: lsalazar@ispm.unibe.ch
ary 2014; revised: 6 August 2014; accepted: 7 August 2014.
.0000000000000446
0269-9370 Q 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins 2451
Co
2452 AIDS 2014, Vol 28 No 16Introduction
HIV viral load is routinely monitored in paediatric
antiretroviral therapy (ART) programmes in high-
income countries, whereas in sub-Saharan Africa, most
programmes rely on CD4þ or clinical monitoring to
detect treatment failure [1]. However, clinical and
immunological criteria are poor predictors of virological
failure for both children and adults [2,3]. The lack of viral
load monitoring can lead to delayed and unnecessary
switches to second-line therapy, promoting the devel-
opment of resistance and limiting future treatment
options [4,5].
In adults, several modelling studies [6–8] and two
randomized controlled trials [9–11] showed that routine
viral load monitoring may reduce mortality slightly and
substantially increase costs. These results cannot be
generalized to children: progression of HIV is faster in
children than in adults, the CD4þ declines with age and
ART regimens differ [1,12–14]. ART coverage in
treatment-eligible children was only about 30% in 2012
in sub-Saharan Africa, much lower than in treatment-
eligible adults [15,16]. As coverage increases and eligibility
criteria change, the question on how to best monitor ART
becomes more important.
Few studies have assessed ART monitoring in children.
One modelling study [17] found the optimal viral load
monitoring strategy to be yearly monitoring, along
with a first measurement 6 months after treatment start, as
recommended by the WHO [1]. The authors estimated
that the strategy would entail a three-fold increase in
the costs of treatment [17]. A recent randomized trial
found that routine CD4þ and toxicity monitoring
conferred minimal benefitswhen compared with monitor-
ing based on clinical progression and toxicity alone [18].
There is no empirical study that compared viral load
and CD4þ monitoring in children. We developed a
mathematical model for HIV progression in children on
ART in Southern Africa to address this question.Materials and methods
Data sources and eligibility criteria
We analysed data on children aged less than 16 years from
seven South African cohorts participating in the
International epidemiologic Databases to Evaluate AIDS
in Southern Africa (IeDEA-SA) collaboration to para-
meterize the model [19,20]: Gugulethu and Khayelitsha
townships, Tygerberg Hospital and Red Cross Hospital in
Cape Town; Rahima Moosa Mother and Child Hospital
and Harriet Shezi Children’s Clinic in Johannesburg;
McCord Hospital in Durban. We included all children
who started ART 2000–2012 with two nucleosidepyright © Lippincott Williams & Wilkins. Unauthoreverse transcriptase inhibitors (NRTIs) and either a
nonnucleoside reverse transcriptase inhibitor (NNRTI)
or a protease inhibitor. We excluded children who started
with ritonavir and NRTIs: this regimen is no longer used
[21–23].
All cohorts measure viral load routinely. The 2004 South
African guidelines recommended 6-monthly viral load
monitoring. Decisions to switch therapy following
virological failure were taken after assessing growth,
CD4þ measures and adherence [24]. Since 2010, the
guidelines recommend viral load monitoring after
6 months, 12 months and yearly thereafter. If viral load
is more than 400 copies/ml, children and caretakers are
counselled for adherence [25]. If viral load is more than
1000 copies/ml, it is measured again 3 months later and if
confirmed switching to second-line ART is recom-
mended. Children failing a protease inhibitor-based
regimen are switched only if adherence was high and drug
resistance documented [25].
Statistical analyses and model structure
We analysed the cohorts to estimate the parameters
for a mathematical model (see Table 1 and Appendix
Table S1, http://links.lww.com/QAD/A570 for a list
of parameters). We fitted Weibull, exponential and
piecewise exponential cumulative distribution func-
tions to time from ART start to virological failure
(>1000 copies/ml); drop in CD4þ percentage to less
than 15 and less than 10% in children aged less than
5 years or drop in CD4þ to less than 200 and less than
100 cells/ml in children aged at least 5 years; and death.
We defined a drop below the upper CD4þ thresholds as
immunosuppression. The lower CD4þ thresholds corre-
spond to WHO immunological failure criteria [1] and we
refer to a drop to below these thresholds as immuno-
logical failure. We also fitted exponential cumulative
distribution functions for time from virological failure to
the first CD4þmeasurement below the above-mentioned
thresholds. We analysed immunological progression
stratified by virological status (failure or no failure) and
mortality stratified by immunological status (no immuno-
suppression, immunosuppression or immunological
failure). We used a demographic model for Africans in
the Western Cape 2007 [26] to estimate HIV-free
mortality, as in a previous study in adults [27].
We formulated a multistate model for HIV progression in
children on ARTand implemented it using the R package
gems [28]. Simulated children were assigned baseline
characteristics including age, sex, ART regimen and
exposure to prevention of mother-to-child transmission
(PMTCT) prophylaxis, based on the cohort data.
Children progressed through 26 states combining several
strata of viral load, CD4þ measures and death (see
Appendix Text S1 and S2, http://links.lww.com/QAD/
A570, Figure S1 and S2, http://links.lww.com/QAD/
A570). We defined two viral load categories (failure andrized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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2454 AIDS 2014, Vol 28 No 16no failure) and three CD4þ categories (no immuno-
suppression, immunosuppression and immunological
failure). For each pair of states, we specified the hazard
function of the transition. Times for all possible
transitions were sampled from each state; the first event
determined the patient’s next state.
Monitoring and switching strategies
We modelled three strategies separately for children
who started ART aged less than 5 and at least 5 years:
6-monthly CD4þ monitoring, switching according to
WHO immunological criteria [1]; 6-monthly viral load
monitoring; and viral load monitoring yearly (as well as an
additional first measurement 6 months after initiation).
For both CD4þ and viral load monitoring, we required a
second measurement 3 months later to confirm failure.
The child was switched to second-line ART immediately
after confirmed failure unless he or she was on a protease
inhibitor first-line regimen and aged less than 3 years at
the time of failure as recommended by the WHO [1].
Second-line ART was assumed to be as effective as first-
line ART.
Outcomes
The main outcomes of interest were mortality, pro-
portion of children who experienced immunological
failure, proportion of children who switched to second-
line therapy, proportion of unnecessary switches (i.e.
without virological failure) and time spent on failing
NNRTI-based and protease inhibitor based ART. We
report all outcomes at 5 years from ART start.
Analysis I: Effect of viral load monitoring using
cohort parameter values
In a first analysis, we simulated 100 000 children for each
monitoring strategy and age group, that is 600 000 in
total. We used parameter values from the statistical
analyses of the South African cohorts. In addition to the
5-year outcomes, we also report cumulative incidences of
mortality and immunological failure, and cumulative time
spent on failing ART over the first 5 years. We assigned
NNRTI or protease inhibitor based first-line regimens
according to the distribution observed in the cohorts. In
this analysis, we assumed a Weibull hazard of virological
failure (Table 1).
Analysis II: Effect of viral load monitoring for
different treatment efficacy scenarios
The South African programmes with frequent laboratory
monitoring and effective regimens based on ritonavir-
boosted lopinavir (LPV/r) [29–31] differ from those in
other countries in Southern Africa. Moreover, the scale-
up of PMTCT may have affected treatment efficacy. We
therefore simulated cohorts of 100 000 children for all
three monitoring strategies with virological failure rates
increasing in steps of 0.01 from 0.01/year to 0.30/year,
approximating the failure rate that corresponds to the risk
reported in a systematic review [32]. In this analysis andpyright © Lippincott Williams & Wilkins. UnauthoAnalysis III, we assumed first-line ART to be NNRTI-
based and second-line ART to be protease inhibitor
based, and a constant virological failure rate over time.
Analysis III: Effect of viral load monitoring
assuming that it improves adherence
We assumed that viral load monitoring prevents
virological failure by improving adherence [33]. We
calculated the rate ratio between unconfirmed (one viral
load measurement >1000 copies/ml) and confirmed
failure (two values >1000 copies/ml) rates from the data.
We used this ratio as a proxy for the ratio of virological
failure rates in sites without and with routine viral load
monitoring, mimicking a retrospective study of viral
load in stored blood samples in CD4þmonitoring sites. In
sites with routine viral load monitoring, a first high viral
load triggers adherence counselling. If the second value is
also elevated, the patient is switched and viral load
becomes undetectable. Without viral load monitoring,
the first elevated viral load value is missed, there is no
adherence counselling and we expect viral load to remain
high. We used the same range of failure rates for CD4þ
monitoring as in Analysis II and simulated cohorts of
100 000 children for all three monitoring strategies. The
virological failure rates with viral load monitoring were
calculated by dividing the rate in the CD4þ monitoring
simulation by the rate ratio between unconfirmed and
confirmed failure.
Additional analyses
In additional analyses, on the basis of Analysis I, we
introduced a hypothetical scenario with no monitoring
and no switching to second-line ART and compared
mortality at 5 years between the no monitoring and
the three monitoring strategies, both for all children and
for children who experienced virological failure. Finally,
we compared predicted outcomes under the different
monitoring strategies with outcomes observed in the
IeDEA-SA cohorts.Results
Description of study population
The dataset consisted of 11 903 children who were
followed up for 30 633 person-years (Appendix Table S2,
http://links.lww.com/QAD/A570). Median age at ART
start was 3.6 years [interquartile range (IQR) 1.0–7.5].
Median baseline CD4þ percentage was 15.6% [inter-
quartile range (IQR) 10.0–22.8] for age less than 5 years,
and median baseline CD4þ 231 cells/ml (IQR 80–424)
for age at least 5 years. Median follow-up duration was 2.1
years (IQR 0.7–4.2). The number of children followed
for more than 48 weeks on first-line ART was 8363
(70.3%). A total of 1317 children (11.1%) were lost to
follow-up, that is had not been seen in the clinic for at
least 1 year. The number of children who had sufficientrized reproduction of this article is prohibited.
Monitoring of paediatric ART Salazar-Vizcaya et al. 2455measurements to detect and confirm treatment failures
was 6484 for viral load and 7036 for CD4þ monitoring.
The median number of months between laboratory
measurements was 5.7 (IQR 4.3–7.2) for viral load and
6.1 (IQR 5.3–7.4) for CD4þ. The majority of children
(57%) started with an NNRTI-based first-line regimen;
the most common NNRTI was efavirenz (EFV, 94%).
The remaining children (43%) started with a LPV/r-based
regimen.
Analysis I: Effect of viral load monitoring using
cohort parameter values
With CD4þ monitoring, about 1.1% of children
switched therapy within the first 5 years of follow-up,
whereas in both viral load monitoring scenarios, the
corresponding proportion was above 12% (Table 2,
Fig. 1a). The mean time spent on failing regimens
decreased from 6.6 months with CD4þ monitoring to
3.6 months with 12-monthly and 3.3 months with
6-monthly viral load monitoring (Fig. 1c). The time
spent on failing NNRTI-based regimens was reduced by
73%, but the time spent on failing protease inhibitor-
based regimens increased slightly when comparing
12-monthly viral load monitoring with CD4þ monitor-
ing (Appendix Figure S3, http://links.lww.com/QAD/
A570). With CD4þ monitoring, 44% of children who
switched to second-line ART switched without virolo-
gical failure, and 97% of virological failures had been
missed. With 6-monthly viral load monitoring, the
proportion of missed failures dropped to 10% (Table 2).
Viral load monitoring did not reduce mortality. Mortality
at 5 years was 7.1% with CD4þ monitoring and 6.9%
with both viral load monitoring strategies (Table 2). TheCopyright © Lippincott Williams & Wilkins. Unaut
Table 2. Key model outcomes for different monitoring strategies.
Type of monitoring CD4
Period between measurements (months)
Children aged <5 years at ART start
Switched to second line (%)
Switched unnecessarily (%)a
Virological failures missed (%)
Mean time spent on failing regimen (months)
Mortality (%)
Children aged 5 to <16 years at ART start
Switched to second-line ART (%)
Switched unnecessarily (%)a
Failures missed (%)
Mean time spent on failing regimen (months)
Mortality (%)
All children (aged <16 years at ART start)
Switched to second line (%)
Switched unnecessarily (%)a
Virological failures missed (%)
Mean time spent on failing regimen (months)
Mortality (%)
All results refer to Analysis I. Percentages refer to the proportion after 5 ye
aProportion of all children who switched to second-line who switched with
unnecessary switches.
bAs recommended by the WHO [1].proportion of children who experienced immunologic
failure was 1.6% with CD4þ monitoring, but 1.0% with
viral load monitoring (Fig. 1b), a 40% reduction.
Analysis II: Effect of viral load monitoring for
different treatment efficacy scenarios
In Fig. 2, we present predicted 5-year treatment
outcomes by rate of virological failure and include the
observed virological failure rates from three recent studies
[18,34,35]. The rates in these studies ranged from 0.05 in
the ARROW trial [18] to 0.17 in the routine programme
in Cambodia [34]. The percentage of children switched
to second-line ARTwas much higher with viral load than
with CD4þ monitoring (Fig. 2a), and the difference
increased with increasing virological failure rates. The
differences in the percentage of children who developed
immunological failure (Fig. 2b), and in the time spent on
a failing regimen (Fig. 2c) also increased with the rate of
virological failure. For the highest virological failure rate
assumed (0.30/year), 12-monthly viral load monitoring
decreased the proportion of children with immunological
failure from 4.2 to 2.5% and the mean time spent on a
failing NNRTI regimen from 27.1 to 5.9 months,
compared with CD4þ monitoring. The mean time spent
on a failing protease inhibitor regimen increased from
0.2 months with CD4þ monitoring to 8.0 months with
12-monthly viral load monitoring. Consistent with
Analysis I, mortality was similar for the three monitoring
strategies.
Analysis III: Effect of viral load monitoring
assuming that it improves adherence
The rate of unconfirmed failure was 0.12/year and the
rate ratio of unconfirmed to confirmed failure was 2.08 inhorized reproduction of this article is prohibited.
þ monitoring VL monitoring
6 6 12b
0.3 6.9 6.0
41.0 0.0 0.0
97.6 9.3 19.1
6.7 5.1 5.3
10.4 10.1 10.3
1.7 20.4 18.1
45.6 0.0 0.0
95.9 9.5 19.4
6.5 1.6 2.1
4.0 3.9 3.9
1.1 13.9 12.1
44.1 0.0 0.0
96.7 9.5 19.6
6.6 3.3 3.6
7.1 6.9 6.9
ars of follow-up. ART, antiretroviral therapy; VL, viral load.
out virological failure. By definition, VL monitoring does not lead to
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 1. Predicted treatment outcomes over 5 years according
to different monitoring strategies (Analysis I). (a) Proportion
of children switching to second-line therapy; (b) Proportion of
children who ever experienced immunological failure; (c)
Mean time spent on failing ART. ART, antiretroviral therapy;
VL, viral load.
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Fig. 2. Predicted treatment outcomes over 5 years according
to different monitoring strategies for varying virological
failure rates (Analysis II). Failure rates estimated for the
ARROW trial [18] (1), Zhao et al. [35] (2), Janssens et al.
[34] (3) are shown with vertical lines. The equivalent constant
rate of virological failure for South African IeDEA data is 0.05.
(a) Proportion of children switching to second-line therapy;
(b) Proportion of children who ever experienced immuno-
logical failure; (c) Mean time spent on failing ART. ART,
antiretroviral therapy; VL, viral load.
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(c)the South African cohort data. We therefore assumed that
with CD4þ monitoring, the virological failure rate was
2.08-fold higher than with viral load monitoring. With
the highest failure rates (0.30/year for CD4þmonitoring,
0.14/year with viral load monitoring), predicted 5-year
mortality was 7% in all monitoring strategies. As
expected, the difference in the percentage of children
switched to second-line ART between viral load and
CD4þ monitoring was smaller than in Analysis II
(Fig. 3a). The percentage of children who experienced
immunological failure was 4.2% with CD4þ and 1.5%
with 12-monthly viral load monitoring (Fig. 3b), and the
mean time spent on failing ART was 27.3 months (27.1
on NNRTI, 0.2 on protease inhibitor) with CD4þ and
6.0 months (3.0 on NNRTI, 3.0 on protease inhibitor)
with viral load monitoring (Fig. 3c). Compared with
CD4þ monitoring, viral load monitoring thus prevented
63% of immunological failures and decreased the average
time spent on a failing regimen by 21 months (a 78%
relative reduction).
Additional analyses
As expected, mortality was slightly higher at 5 years with
the hypothetical no monitoring and no switching
scenario; 7.2 compared with 6.9% with viral load
monitoring (Appendix Figure S4, http://links.lww.
com/QAD/A570). Differences in mortality were more
pronounced when restricting the analyses to children
who experienced virological failure (Appendix Figure S5,
http://links.lww.com/QAD/A570). Unsurprisingly,
modelled outcomes under the different monitoring
strategies were similar to the outcomes observed in the
IeDEA-SA cohorts (Appendix Table S3, http://links.
lww.com/QAD/A570).10
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Fig. 3. Predicted treatment outcomes over 5 years assuming
that viral load monitoring reduces the virologic failure
(Analysis III). We assumed that replacing CD4þ monitoring
by VL monitoring could reduce the rate of virological failure
by a factor of 2.08 as estimated from the data (see details in
methods). (a) Proportion of children switching to second-line
therapy; (b) Proportion of children who ever experienced
immunological failure; (c) Mean time spent on failing ART.
ART, antiretroviral therapy; VL, viral load.Discussion
This mathematical modelling study showed that routine
viral load monitoring does not reduce mortality of
children during the first 5 years on ART. However, a
clear benefit of viral load monitoring was evident in
terms of preventing immunodeficiency through more
timely identification of virological failure. Viral load
monitoring substantially increased the demand for
second-line ART, but it also prevented many unnecess-
ary switches and reduced the average time spent on
failing ART by at least 3 months. Outcomes were very
similar with 6-monthly and 12-monthly viral load
monitoring, suggesting that the WHO recommen-
dation of 12-monthly viral load tests is appropriate
[1].
The lack of any important effect on mortality is consistent
with the results of modelling studies in adults [6–8],
suggesting that viral load monitoring will improve
survival only minimally in the short term. The mainCopyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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the first few months of ART, which is not influenced
by the approach taken to monitoring but driven by
immunosuppression at the start of therapy. Virological
failure does not directly influence mortality and
immunological progression is relatively slow. Indeed,
only few children who failed virologically progressed to
immunological failure during the 5-year follow-up time.
This situation may change with the increase of CD4þ and
CD4þ percentage at the start of ART: early HIV-related
mortality will probably become less important and the
type of monitoring more important. Furthermore, in the
longer term, children followed up with CD4þ monitor-
ing only will increasingly be exposed to virological failure
and immunosuppression, which will eventually translate
into increased mortality. As could be expected, the
differences in mortality were more substantial in the (few)
children who failed virologically, that is the children who
are likely to benefit from a timely switch to second-line
ART. Of note, prolonged viraemia may have other
sequelae, including, for example, deficits in neurodeve-
lopment [36,37].
In the South African cohorts, almost half of the children
started ARTon a protease inhibitor-based regimen. This
proportion was higher in the youngest children: almost
90% of children aged less than 3 years at ART start started
with protease inhibitor-based first-line regimen. One
year of a protease inhibitor-based regimen can cost more
than USD 400, whereas 1 year of a standard NNRTI-
based regimen costs between USD 50 and USD 200 [38].
In South Africa, switching to second-line ARTaccording
to WHO recommendations [1] might therefore reduce
rather than raise costs. However, switching children from
a failing protease inhibitor-based to NNRTI-based
regimens is controversial. Low rates of viral suppression
on second-line therapy have been reported in this
situation [39] and the risk for protease inhibitor and
NRTI resistance mutations during exposure to unsuc-
cessful protease inhibitor-based ART may be low [29].
Our model was not designed to account for switches from
protease inhibitor-based regimens to the alternatives that
are now becoming available in South Africa. The
situation is different in other countries in the region:
in the IeDEA-SA cohorts from outside South Africa, very
few children started with protease inhibitor-based ART
[40].
We did not consider drug resistance explicitly. If viral load
is not routinely monitored, children failing virologically
can spend years on a failing regimen and develop
resistance, which will decrease the efficacy of second-line
regimens. Drug resistance has often been observed in
paediatric cohorts [41–43], related to exposure to
PMTCT drugs and poor adherence to ART [41,44].
The risk of resistant mutations is higher in settings using
NNRTI-based rather than protease inhibitor-based first-
line regimens [29]. An important finding of our study ispyright © Lippincott Williams & Wilkins. Unauthothat across a range of virological failure rates, viral load
monitoring decreased the time spent on a failing regimen
by over 50%. Our study thus supports the notion that viral
load monitoring may reduce the risk of drug resistance.
Nevertheless, other interventions, such as better adher-
ence counselling or improved sequencing of regimens,
may be more realistic approaches to prevent drug
resistance than viral load monitoring [31,44].
Our study has other limitations. Guidelines and clinical
practice in South Africa changed over the study period
and the data used to parameterize the model may not
reflect current practice. For example, due to the trend to
earlier ART initiation, children are now healthier at ART
start than previously [45]. Furthermore, because PMTCT
coverage has increased, children are more likely to have
been exposed to antiretrovirals in utero [16]. The efficacy
of drugs and the effectiveness of ART programmes
have improved. We did not explicitly model these trends,
but incorporated them implicitly by varying virological
failure rates. Outcomes were modelled only up to 5 years
after starting ART because of the limited availability of
long-term data.
Eleven percent of children in the data were lost to
follow-up at 5 years. Censoring patients who are lost to
follow-up can lead to programme-level mortality being
underestimated because mortality is higher among
those lost to follow-up than among patients remaining
in care [46,47]. However, our objective was to model
the influence of different monitoring strategies on the
outcomes of children remaining in care. It was not our
intention to examine programme-level outcomes and
include outcomes in children lost to follow-up.
Interestingly, our results are closely similar to a recent
multiregional analysis of paediatric outcomes of ART in
Africa and Asia [48]. Leroy et al. [48] used a competing
risk model of death and loss to follow-up. They therefore
estimated mortality during follow-up only; mortality in
patients lost to follow up was not considered. Their
estimate at 18 months was 6.2% for Southern Africa, very
close to our estimate of about 6.0%. It therefore seems
likely that our modelled estimates of mortality reflect
mortality among children remaining in care. As
expected, our estimates were also compatible with the
cumulative mortality and failure observed in the cohort
data.
Adherence was also not included explicitly in our model.
Viral load monitoring helps detect poor adherence and
identifies children and caretakers who need counselling,
which in turn may reduce the risk of virological failure.
We examined this scenario in the third analysis but again
found that mortality was not reduced, even when
assuming lower failure rates with viral load monitoring.
However, the beneficial effect on immunological out-
comes and the reduction in time spent on failing
treatment became more pronounced when assuming thatrized reproduction of this article is prohibited.
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monitoring. In both the second and third analysis, we
assumed constant failure rates, which do not reflect the
decreasing hazard of virological failure observed in the
cohorts. We may thus have underestimated the time a
child is exposed to an increased risk of death. However,
despite the wide range of virological failure rates assumed
in our models, we did not observe differences in mortality
between strategies. Mortality is thus unlikely to decrease
in the short term with viral load monitoring, even if the
rate of virological failure is high.
Conclusion
In this modelling study, viral load monitoring did not
improve survival compared with CD4þ monitoring over
5 years of ART, but several other benefits of viral load
monitoring were evident. Provided that appropriate
second-line therapy is available, viral load monitoring can
avert progression to immunosuppression, reduce the time
spent on a failing regimen and prevent unnecessary
switches to second-line ART. We intend to repeat this
analysis in due time to gain insights into the effects of
different monitoring strategies on long-term outcomes,
and the modifying effect of less advanced immunosup-
pression at the start of ART. Further research is also
needed to gain a better understanding of the causal
relationships between adherence, virological failure and
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